Conversely, low-dose GLP-1 therapy is not appropriate for patients without established indications, particularly those seeking anti-inflammatory effects alone without diabetes or obesity
This effect is part of the entero-insular axis of glucose homeostasis and is estimated to be responsible for at least 50% of insulin secretion [2, 3]
In December 2025, this breakthrough technology expanded to weight management when the FDA approved the Wegovy pill the first oral GLP-1 medication specifically for obesity and weight loss
at Better Med Spa it is planned to be offered once clinical approval occurs
The CV risk markers improved, but surrogate endpoints aren't SELECT
That means evaluating the patient, reviewing medical history, considering lab work, discussing realistic goals, and monitoring response over time